Wetenschappelijke artikelen

2018

  • Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, ten Klooster PM, Tekstra J, Schilder AM, et al. Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. PLoS One. 2018;13(5):e0192425. 
  • Tran-Duy A, Ghiti Moghadam M, Oude Voshaar MAH, Vonkeman HE, Boonen A, Clarke P, et al. An Economic Evaluation of Stopping versus Continuing TNF-Inhibitor Treatment in Rheumatoid Arthritis Patients in Remission or Low Disease Activity: results from the POET randomized trial. Arthritis Rheumatol. 2018;70(10):1557-1564.
  • Steunebrink LMM, Versteeg LGA, Vonkeman HE, ten Klooster PM, Hoekstra M, van de Laar MAFJ. Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry. BMC Rheumatol. 2018;2(1):1. 
  • Steunebrink LMM, Oude Voshaar MAH, Taal E, Vonkeman HE, Zijlstra TR, van de Laar MAFJ. Determinants of perceived health non-improvement in early rheumatoid arthritis patients with favorable treatment outcomes. Arthritis Care Res (Hoboken). 2018;70(4):510-515.
  • Ghiti Moghadam M, Ten Klooster PM, Vonkeman HE, Kneepkens EL, Klaasen R, Stolk JN, et al. Impact of Stopping Tumor Necrosis Factor-inhibitors on Rheumatoid Arthritis Patients' Burden of Disease. Arthritis Care Res (Hoboken). 2018;70(4):516-524. 
  • Rongen GA, van Ingen I, Kok M, Vonkeman H, Janssen M, Jansen TL. Vasodilator function worsens after cessation of tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis only if a flare occurs. Clin Rheumatol. 2018;37(4):909-916.
  • Versteeg GA, Steunebrink LMM, Vonkeman HE, ten Klooster PM, van der Bijl AE, van de Laar MAFJ. Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice. Clin Rheumatol. 2018;37(5):1189-1197.

2017

  • Oude Voshaar MAH, Moghadam MG, Vonkeman HE, ten Klooster PM, van Schaardenburg D, Tekstra J, et al. Measuring Disease Exacerbation and Flares in Rheumatoid Arthritis: Comparison of Commonly Used Disease Activity Indices and Individual Measures. J Rheumatol. 2017;44(8):1118-1124.

2016

  • Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, et al. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial. Arthritis Rheumatol (Hoboken, NJ). 2016;68(8):1810–7.
  • Manders SHM, Kievit W, Jansen TLTA, Stolk JN, Visser H, Schilder AM, et al. Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry. J Rheumatol. 2016;43(10):1787-1794.
  • Steunebrink LMM, Vonkeman HE, Ten Klooster PM, Hoekstra M, van Riel PLCM, van de Laar MAFJ. Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry. Clin Rheumatol. 2016;35(3):609–15.
  • Steunebrink LMM, Versteeg GA, Vonkeman HE, ten Klooster PM, Kuper HH, Zijlstra TR, et al. Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry. Arthritis Res Ther. 2016;18(1):60.
  • van den Reek JMPA, Pijls PARR, Tummers M, van Riel PCLM, Kievit W, Hoentjen F, et al. Adalimumab drug survival in patients with psoriasis, Crohn’s disease, and rheumatoid arthritis: Relevant differences using the same treatment. J Am Acad Dermatol. 2016;74(1):177–9.

2015

  • Kearsley-Fleet L, Závada J, Hetland ML, Nordström DC, Aaltonen KJ, Listing J, Zink A, Gati T, Rojkovich B, Iannone F, Gremese E, van Riel PL, van de Laar MA, Lie E, Kvien TK, Canhão H, Fonseca JE, Rotar Ž, Loza E, Carmona L, Askling J,Johansson K, Finckh A, Dixon WG, Hyrich KL; EULAR Study Group for Registers and Observational Drug Studies. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology (Oxford). 2015;54(6):1074-9.
  • Koop SM, ten Klooster PM, Vonkeman HE, Steunebrink LM, van de Laar MA. Neuropathic-like pain features and cross-sectional associations in rheumatoidarthritis. Arthritis Res Ther. 2015 Sep 3;17:237.
  • Manders SH, van de Laar MA, Rongen-van Dartel SA, Bos R, Visser H, Brus HL, Jansen T, Vonkeman HE, van Riel PL, Kievit W. Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry. RMD Open. 2015;1(1):e000147.
  • Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE, Hendrikx J, Jansen TL, Westhovens R, van de Laar MA, van Riel PL. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Res Ther. 2015;17:134.
  • Manders SH, Kievit W, Adang E, Jansen TJ, Stolk JN, Visser H, Schilder AM, Vonkeman HE, van de Laar MA, van Riel PL. Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice. Ann Rheum Dis. 2015;74(3):e24.
  • Nikolaus S, Bode C, Taal E, Vonkeman HE, Glas CA, van de Laar MA. Construct Validation of a Multidimensional Computerized Adaptive Test for Fatigue in Rheumatoid Arthritis. PLoS One. 2015;10(12):e0145008.
  • Oude Voshaar MA, Ten Klooster PM, Glas CA, Vonkeman HE, Taal E, Krishnan E,Bernelot Moens HJ, Boers M, Terwee CB, van Riel PL, van de Laar MA. Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures. Rheumatology (Oxford). 2015;54(12):2221-9.
  • Oude Voshaar MA, Ten Klooster PM, Bode C, Vonkeman HE, Glas CA, Jansen T, van Albada-Kuipers I, van Riel PL, van de Laar MA. Assessment of fatigue in rheumatoid arthritis: a psychometric comparison of single-item, multiitem, and multidimensional measures. J Rheumatol. 2015;42(3):413-20.
  • Ten Klooster PM, Vonkeman HE, Oude Voshaar MA, Siemons L, van Riel PL, van de Laar MA. Predictors of satisfactory improvements in pain for patients with early rheumatoid arthritis in a treat-to-target study. Rheumatology (Oxford). 2015;54(6):1080-6.
  • Umićević Mirkov M, Janss L, Vermeulen SH, van de Laar MA, van Riel PL,Guchelaar HJ, Brunner HG, Albers CA, Coenen MJ. Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(12):2183-7.

2014

  • Manders SHM, Kievit W, Braakman-Jansen ALMA, Brus HLM, Hendriks L, Fransen J, et al. Determinants associated with work participation in patients with established rheumatoid arthritis taking tumor necrosis factor inhibitors. J Rheumatol. 2014;41(7):1263–9.
  • Okada Y, Wu D, Trynka G, Raj T, Terao C. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. Nature Publishing Group; 2014;506(7488):376–81.
  • Oude Voshaar MA, Ten Klooster PM, Glas CA, Vonkeman HE, Taal E, Krishnan E, et al. Calibration of the PROMIS physical function item bank in Dutch patients with rheumatoid arthritis. PLoS One. 2014;9(3):e92367.
  • Oude Voshaar MAH, Ten Klooster PM, Glas CAW, Vonkeman HE, Krishnan E, van de Laar MAFJ. Relative performance of commonly used physical function questionnaires in rheumatoid arthritis and a patient-reported outcomes measurement information system computerized adaptive test. Arthritis Rheumatol (Hoboken, NJ). 2014;66(10):2900–8.
  • Siemons L, ten Klooster PM, Vonkeman HE, Glas CAW, van de Laar MAFJ. Distinct trajectories of disease activity over the first year in early rheumatoid arthritis patients following a treat-to-target strategy. Arthritis Care Res. 2014;66(4):625–30.
  • Siemons L, Ten Klooster PM, Vonkeman HE, van de Laar MAFJ, Glas CAW. Further optimization of the reliability of the 28-joint disease activity score in patients with early rheumatoid arthritis. PLoS One. 2014;9(6):e100544.
  • Siemons L, Vonkeman HE, Ten Klooster PM, van Riel PLCM, van de Laar MAFJ. Interchangeability of 28-joint disease activity scores using the erythrocyte sedimentation rate or the C-reactive protein as inflammatory marker. Clin Rheumatol. 2014;33(6):783–9.
  • Siemons L, Ten Klooster PM, Vonkeman HE, van Riel PL, Glas CA, van de Laar MA. How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. BMC Musculoskelet Disord. 2014;15(1):368.
  • Tran-Duy A, Boonen A, Kievit W, van Riel PLCM, van de Laar MAFJ, Severens JL. Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis. Pharmacoeconomics. 2014;32(10):1015–28.

2013

  • Oude Voshaar MAH, Ten Klooster PM, Vonkeman HE, Kievit W, van Riel PLCM, van de Laar MAFJ. Measurement bias in different versions of the Dutch Health Assessment Questionnaire Disability Index. Ann Rheum Dis. 2013;72(12):2050–1. 
  • Oude Voshaar MA, Glas CA, Ten Klooster PM, Taal E, Wolfe F, van de Laar MA. Crosscultural Measurement Equivalence of the Health Assessment Questionnaire II. Arthritis Care Res. 2013;65(6):1000–4.
  • Siemons L, Ten Klooster PM, Taal E, Kuper IH, van Riel PL, Glas CA, et al. Contribution of assessing forefoot joints in early rheumatoid arthritis patients: insights from item response theory. Arthritis Care Res. 2012/07/19. 2013;65(2):212–9.
  • ten Klooster PM, Oude Voshaar MA, Gandek B, Rose M, Bjorner JB, Taal E, et al. Development and evaluation of a crosswalk between the SF-36 physical functioning scale and Health Assessment Questionnaire disability index in rheumatoid arthritis. Heal Qual Life Outcomes. 2013;11:199.
  • ten Klooster PM, Vonkeman HE, Taal E, Siemons L, Hendriks L, de Jong AJL, et al. Performance of the Dutch SF-36 version 2 as a measure of health-related quality of life in patients with rheumatoid arthritis. Heal Qual Life Outcomes. 2013;11:77.
  • Umiċeviċ Mirkov M, Cui J, Vermeulen SH, Stahl EA, Toonen EJM, Makkinje RR, et al. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72(8):1375–81. 
  • van Dartel SAA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis. 2013;72(6):895–900.
  • van Dartel SAA, Fransen J, Kievit W, Dutmer EAJ, Brus HLM, Houtman NM, et al. Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford). 2013;52(6):1052–7.
  • Vermeer M, Kievit W, Kuper HH, Braakman-Jansen LM, Bernelot Moens HJ, Zijlstra TR, et al. Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. BMC Musculoskelet Disord. 2013;14(1):350.
  • Vermeer M, Kuper HH, Moens HJB, Drossaers-Bakker KW, van der Bijl AE, van Riel PLCM, et al. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort. Arthritis Care Res (Hoboken). 2013;65(8):1219–26.

2012

  • Buitinga L, Braakman-Jansen LM, Taal E, Kievit W, Visser H, van Riel PL, et al. Comparative responsiveness of the EQ-5D and SF-6D to improvement in patients with rheumatoid arthritis treated with TNF-blockers: Results of the DREAM registry. Arthritis Care Res. 2012;64(6):826–32.
  • de Punder YMR, Fransen J, Kievit W, Houtman PM, Visser H, van de Laar M a FJ, et al. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford). 2012;51(9):1610–7.
  • Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Broeder AA Den, et al. A Tight Control Treatment Strategy Aiming for Remission in Early Rheumatoid Arthritis Is More Effective than Usual Care Treatment in Daily Clinical Practice: A Study of Two Cohorts in the Dutch Rheumatoid Arthritis Monitoring Registry. Ann Rheum Dis. 2012;71(1):845–50.
  • Vermeer M, Kuper HH, Bernelot Moens HJ, Hoekstra M, Posthumus MD, van Riel PL, et al. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther. 2012;14(6):R254.
  • Vermeer M, Kuper HH, van der Bijl AE, Baan H, Posthumus MD, Brus HL, et al. The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion. Rheumatol. 2012;51(6):1076–80.

2011

  • Arts EEA, Jansen TL, Den Broeder A, Vonkeman HE, Dutmer E, Van de Laar MAFJ, et al. Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis. 2011;70(5):877–8.
  • Blom M, Kievit W, Donders a RT, den Broeder A a, Straten VHHP, Kuper I, et al. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis. J Rheumatol. 2011;38(11):2355–61.
  • Kievit W, Fransen J, Adang EMM, den Broeder A a, Bernelot Moens HJ, Visser H, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford). 2011;50(1):196–203.
  • Schipper LG, Kievit W, den Broeder AA, van der Laar MA, Adang EMM, Fransen J, et al. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford). 2011;50(7):1320–30.
  • Siemons L, Ten Klooster PM, Taal E, Kuper IH, van Riel PL, van de Laar MA, et al. Validating the 28-tender joint count using item response theory. J Rheumatol. 2011;38(12):2557–64.
  • Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum. 2011;63(10):2865–72.

2010

  • Blom M, Kievit W, Kuper HH, Jansen TL, Visser H, den Broeder AA, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res (Hoboken). 2010;62(9):1335–41.
  • Coenen MJH, Enevold C, Barrera P, Schijvenaars MMVAP, Toonen EJM, Scheffer H, et al. Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcome. PLoS One. 2010;5(12):e14326.
  • Kievit W, Hendrikx J, Stalmeier PF, van de Laar MA, Van Riel PL, Adang EM. The relationship between change in subjective outcome and change in disease: a potential paradox. Qual Life Res. 2010;19(7):985–94.

2009

  • Blom M, Kievit W, Fransen J, Kuper IH, den Broeder AA, De Gendt CMA, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol. 2009;36(10):2171–7.
  • Kievit W, Fransen J, Adang EM, Kuper HH, Jansen TL, De Gendt CMA, et al. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies. Ann Rheum Dis. 2009;68(6):844–9.
  • Radovits BJ, Kievit W, Fransen J, van de Laar MAFJ, Jansen TL, van Riel PLCM, et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68(9):1470–3.

2008

  • Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis. 2008;67(9):1229–34.
  • ten Klooster PM, Veehof MM, Taal E, van Riel PL, van de Laar MA. Confirmatory factor analysis of the Arthritis Impact Measurement Scales 2 Short Form in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59(5):692–8.
  • ten Klooster PM, Taal E, van de Laar MA. Rasch analysis of the Dutch Health Assessment Questionnaire disability index and the Health Assessment Questionnaire II in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59(12):1721–8. 
  • Veehof MM, ten Klooster PM, Taal E, van Riel PL, van de Laar MA. Comparison of internal and external responsiveness of the generic Medical Outcome Study Short Form-36 (SF-36) with disease-specific measures in rheumatoid arthritis. J Rheumatol. 2008;35(4):610–7.
  • Veehof MM, ten Klooster PM, Taal E, van Riel PLCM, van de Laar MAFJ. Psychometric properties of the Rheumatoid Arthritis Disease Activity Index (RADAI) in a cohort of consecutive Dutch patients with RA starting anti-tumour necrosis factor treatment. Ann Rheum Dis. 2008;67(6):789–93.

2007

  • Kievit W, Fransen J, Oerlemans a JM, Kuper HH, van der Laar MA, de Rooij DJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis. 2007;66(11):1473–8.
  • ten Klooster PM, Veehof MM, Taal E, van Riel PL, van de Laar MA. Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment. Ann Rheum Dis. 2007;66(11):1485–90.